Georgia Life Sciences Association Statement on the Release of the NSCEB Final Report and Action Plan

Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in a new era of global competition

Georgia Life Sciences (GLS) applauds the National Security Commission on Emerging Biotechnology (NSCEB) for its leadership and vision in publishing its final report and action plan to Congress. This comprehensive roadmap is a vital step toward securing and advancing U.S. leadership in biotechnology at a critical moment for our nation's competitiveness, security, and economic future.


We strongly support the Commission’s call for urgent federal action, including the proposed $15 billion in new investments over five years, to ensure the U.S. biotechnology sector remains the global leader in innovation and commercialization. These resources will help drive transformative advances across healthcare, manufacturing, national security, and more.


The timing of this report is especially critical as our nation’s life sciences research and innovation infrastructure, particularly at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), faces considerable uncertainty. Strong federal leadership and investment are essential to maintain the momentum of discovery, innovation, and public health progress.


The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework:

  • Prioritize biotechnology at the national level
  • Mobilize the private sector to get U.S. products to scale
  • Maximize the benefits of biotechnology for defense
  • Out-innovate our strategic competitors
  • Build the biotechnology workforce of the future
  • Mobilize the collective strengths of our allies and partners


Georgia Life Sciences encourages members of the Georgia congressional delegation to endorse the Commission’s report and advocate for its swift and full implementation by the administration. Georgia's leadership in life sciences innovation positions our state to be a key contributor in realizing the report’s vision, and federal support is essential to maximizing this opportunity for both regional and national impact.


As Georgia continues to grow its vibrant life sciences ecosystem, we recognize the immense potential of a coordinated national strategy to accelerate innovation, empower our workforce, and foster public-private partnerships. We look forward to working with policymakers, industry partners, and research institutions to implement these recommendations and deliver biotechnology solutions that improve lives and strengthen our country. As the report states, without this type of transformational investment, our adversaries will work to leverage their biotech advancements to attack, destroy, starve, and harm the U.S.


The full text of the final report can be found here: https://biotech.senate.gov 

Announcement: https://www.biotech.senate.gov/press-releases/nsceb-publishes-final-report/

BIO's statement is here.

Biotech Leaders Launch National Alliance to Define the Future of American Innovation

May 5, 2026
New coalition forms to develop a national innovation roadmap to strengthen and extend  America’s global leadership in biotechnology

UGA & Manus Among Awardees in $214M BioMADE Investment

April 30, 2026
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities

Nutrivert announces first close on $6 million Series A-2 funding round

April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
MORE POSTS